Health Professional Radio - Podcast

Dr. Mark Allen, MD, co-founder and CEO of Elevian, developer of therapies to treat age-related diseases like stroke and diabetes, discusses the drug candidate, recombinant growth differentiation factor 11 (rGDF11) with broad therapeutic benefits demonstrated in numerous animal studies. "Science" recognized GDF11 as a top scientific breakthrough calling it “the rejuvenation factor”. Dr. Mark Allen is the co-founder and chief executive officer at Elevian. Dr. Allen has a BS in Applied Physics from Columbia University and an MD from UCLA. During his medical training, he developed one of the first web-based clinical decision support systems to guide ER physicians to make the right patient care decisions. After clinical trials demonstrating significant improvements in healthcare quality and cost, Dr. Allen founded Corticon to bring this new technology to market. Under Dr. Allen’s leadership as CEO, Corticon became one of the leading commercial rules engine software products, powering automated decision-making in